True North Embio Investment: Cyril Amarchand Mangaldas Advises on Minority Stake Deal
Cyril Amarchand Mangaldas (CAM) advised True North on its acquisition of a significant minority stake in Embio Limited — a regulated markets-focused manufacturer of complex APIs and advanced intermediates. The True North Embio investment, announced on June 3, 2026, marks a significant private equity move into India’s specialised pharmaceutical manufacturing sector. This transaction represents the third investment from True North’s Fund VII and its first in the pharmaceuticals sector from that vehicle.
Introduction
Embio Limited has raised growth capital through a minority investment from True North, a leading private equity fund. Embio specialises in the manufacturing of complex, high-value APIs and advanced intermediates with deep expertise in synthetic biology and precision fermentation, and has established a leadership position in controlled substances across several therapeutic areas, including nasal decongestants, ADHD, Parkinson’s disease, and anti-epileptics.
The proceeds from this investment will fuel Embio’s next phase of growth through investments in R&D, talent acquisition, capacity expansion at its Dahej facility, and the scaling of its CDMO business. Avendus Capital acted as the financial advisor to Embio for this capital-raise process.
Legal Teams Involved
Cyril Amarchand Mangaldas acted as legal counsel to True North. The advisory mandate spanned transaction execution, multi-disciplinary due diligence, competition law, intellectual property, employment, and real estate — with separate specialist teams leading each workstream.
Transaction Team
- Aditi Manchanda, Partner
- Abhishek Kalra, Partner
- Naimi Kamdar, Principal Associate
- Chandni Ochani, Principal Associate
- Rajat Pareek, Associate
Due Diligence Team
- Aditi Manchanda, Partner
- Abhishek Kalra, Partner
- Chandni Ochani, Principal Associate
- Kaushik Raichura, Senior Associate
- Rajat Pareek, Associate
Pharma and Healthcare Due Diligence
- Biplab Lenin, Partner
- Anam Chowdhary, Associate
Intellectual Property, Information Technology and Data Privacy Due Diligence
- Arya Tripathy, Partner
- Milind Yadav, Associate
Employment Due Diligence
- Sowmya Kumar, Partner
- Luv Saggi, Director – Employment
- Tara Thakur, Associate
CCI Analysis
- Dhruv Rajain, Partner
- Ridhima Sethi, Associate
Real Estate
- Siddharth Singh, Partner
- Rushi Panchal, Associate
Significance and Impact
True North stated that the investment reflects its confidence in the long-term growth of India’s healthcare and life sciences sector and its focus on backing companies that can compete globally. Founded in 1986, Embio works with bacteria, fungi, and other microorganisms to produce APIs and specialised chiral intermediates, with a manufacturing facility in Maharashtra and a global customer base spanning over 80 markets, including the United States, Europe, Japan, Brazil, Canada, Africa, and the Middle East.
The breadth of the CAM advisory mandate — spanning pharma regulatory, IP, employment, competition, and real estate streams alongside the core transaction team — reflects the complexity of due diligence in India’s tightly regulated controlled substances sector. The deal is also notable as a bellwether for continued private equity interest in specialised, regulated-market API platforms, a segment gaining strategic importance amid global pharmaceutical supply chain realignment. For a broader view of law firm deal activity, see the Deal Meter.
Conclusion
True North has acquired a significant minority stake in Embio Limited, a leading manufacturer of complex APIs and advanced intermediates focused on regulated markets and a key player in the controlled substances sector. Cyril Amarchand Mangaldas provided end-to-end legal counsel across all workstreams of the transaction. Further details on deal value and governance arrangements were not disclosed.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
